Loading clinical trials...

Mechanism of Serum PRL in the Development of MAFLD | Clinical Trials | Clareo Health

UNKNOWN

Mechanism of Serum PRL in the Development of MAFLD

NCT05525884•Shen Qu

Summary

Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently. However, the relationship between serum PRL and MAFLD among diabetic patients is unclear. The investigators aimed to explore the association between serum PRL and the risk of MAFLD in patients with type 2 diabetes (T2DM).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•aged 18\~65 years old,
•underwent the laboratory tests, hepatic ultrasonography, and valid transient elastography (FibroScan) examination

Exclusion Criteria

•other known chronic liver diseases, such as chronic hepatitis B or C, autoimmune hepatitis, and haemochromatosis
•pre-existing active cancer, renal dysfunction, severe liver dysfunction, congestive heart failure or free abdominal fluid
•history of hyperthyroidism or hypothyroidism, pituitary diseases, and other types of diabetes
•significant alcohol consumption
•pregnancy
•receiving any therapeutic methods that could lead to liver steatosis or fibrosis, influence the glucolipid metabolism, or PRL levels, such as lipid-lowering, and PRL-lowering agents (bromocriptine) within 6 months prior to this study.

Locations (1)

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

January 1, 2017

Primary Completion Date

January 1, 2024

Completion Date

January 31, 2024

Last Updated

September 2, 2022

Enrollment

1,000

ESTIMATED participants

Conditions

Type2 DiabetesFatty Liver, NonalcoholicLiver Fibrosis

Interventions

non-invasive method, Fibroscan

OTHER

Contacts

Shen Qu

CONTACT

+862166301064 qushencn@hotmail.com

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444

Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver Fibrosis

View study

RECRUITING

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

NCT04429100

Liver Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 2, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mechanism of Serum PRL in the Development of MAFLD

Inclusion Criteria

Exclusion Criteria

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Biomarkers in the Diagnosis and Prognosis of NAFLD